iBio, Inc. - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

iBio, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'iBio, Inc. - Product Pipeline Review - 2016', provides an overview of the iBio, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by iBio, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc.
- The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses iBio, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features iBio, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate iBio, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for iBio, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding iBio, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
iBio, Inc. Snapshot 6
iBio, Inc. Overview 6
Key Information 6
Key Facts 6
iBio, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
iBio, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
iBio, Inc. - Pipeline Products Glance 13
iBio, Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
iBio, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
iBio, Inc. - Drug Profiles 16
anthrax vaccine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
HAI-05 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
influenza [strain A/H1N1] vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
malaria vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NaAPR1M-74 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
anthrax + plague vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
human papillomavirus [Serotype 16] vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
IBIOCFB-03 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody for Anthrax 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Inhibit Neuraminidase for Influenza 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
palivizumab biosimilar 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
yellow fever vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
influenza [strain A/H7N9] vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinant Protein for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
trypanosomiasis vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
iBio, Inc. - Pipeline Analysis 35
iBio, Inc. - Pipeline Products by Target 35
iBio, Inc. - Pipeline Products by Route of Administration 36
iBio, Inc. - Pipeline Products by Molecule Type 37
iBio, Inc. - Pipeline Products by Mechanism of Action 38
iBio, Inc. - Recent Pipeline Updates 39
iBio, Inc. - Dormant Projects 44
iBio, Inc. - Locations And Subsidiaries 45
Head Office 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

iBio, Inc., Key Information 6
iBio, Inc., Key Facts 6
iBio, Inc. - Pipeline by Indication, 2016 9
iBio, Inc. - Pipeline by Stage of Development, 2016 10
iBio, Inc. - Monotherapy Products in Pipeline, 2016 11
iBio, Inc. - Combination Treatment Modalities in Pipeline, 2016 12
iBio, Inc. - Phase I, 2016 13
iBio, Inc. - Preclinical, 2016 14
iBio, Inc. - Discovery, 2016 15
iBio, Inc. - Pipeline by Target, 2016 35
iBio, Inc. - Pipeline by Route of Administration, 2016 36
iBio, Inc. - Pipeline by Molecule Type, 2016 37
iBio, Inc. - Pipeline Products by Mechanism of Action, 2016 38
iBio, Inc. - Recent Pipeline Updates, 2016 39
iBio, Inc. - Dormant Developmental Projects,2016 44